Table 3.
Risk of retinopathy associated with anti-HCV therapy and treatment duration.
| HCV-Untreated | HCV Patients with Antiviral Therapy (PegIFN/RBV) | |||||
|---|---|---|---|---|---|---|
| Retinopathy | <24 Weeks | p Value | ≥24 Weeks | p Value | ||
| Any retinopathy | Cases | 5 | 5 | 10 | ||
| Person-years | 5032 | 562 | 2194 | |||
| Incidence (10−3) | 0.99 | 8.90 | 4.56 | |||
| HR a (95% CI) | 1.00 (ref) | 11.3 (3.00–42.8) | 0.0003 | 8.18 (2.58–25.9) | 0.00004 | |
| Retinal venous occlusion | Cases | 3 | 2 | 1 | ||
| Person-years | 5032 | 562 | 2194 | |||
| Incidence (10−3) | 0.60 | 3.56 | 0.46 | |||
| HR a (95% CI) | 1.00 (ref) | 6.59 (0.94–46.2) | 0.06 | 0.76 (0.11–5.35) | 0.78 | |
| Retinal arterial occlusion | Cases | 0 | 1 | 0 | ||
| Person-years | 5032 | 562 | 2194 | |||
| Incidence (10−3) | 0.00 | 1.78 | 0.00 | |||
| HR a (95% CI) | 1.00 (ref) | NA | NA | |||
| Retinal hemorrhage | Cases | 1 | 2 | 9 | ||
| Person-years | 5032 | 562 | 2194 | |||
| Incidence (10−3) | 0.20 | 3.56 | 4.10 | |||
| HR a (95% CI) | 1.00 (ref) | 22.0 (1.91–254) | 0.01 | 36.2 (4.19–313) | 0.001 | |
| Unspecified | Cases | 1 | 0 | 0 | ||
| Person-years | 5032 | 562 | 2194 | |||
| Incidence (10−3) | 0.20 | 0.00 | 0.00 | |||
| HR a (95% CI) | 1.00 (ref) | NA | NA | |||
a Adjusted for age, sex, occupation, urbanization, geographical region, monthly income, myocardial infarction, cerebrovascular disease, chronic pulmonary disease, diabetes mellitus, renal disease, hypertension, hyperlipidemia, cataract, diabetic retinopathy, liver cirrhosis, anemia, statin, and competing mortality. Abbreviations: CI, confidence interval; HR, hazard ratio.